Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: KENNETH R SANDERS who wrote (4606)	7/26/1998 9:27:00 PM
From: BigKNY3	Read Replies (4) \| Respond to of 9523

PFE Analyst Roll-Call 7/26/98 Listed below are the PFE ratings, 12 month target prices and recent comments from 18 analysts updated as of 7/26/98 and sorted by PFE rating. Have PFun! BigKNY3 ______________________________________________________ PFE Analyst Roll Call: 7/26/98 Strong Buy/Outperform Broker: Gruntal & Co. Analyst: David F. Saks PFE Rating: Strong Buy Target Price: $148 Comments: 7/24/98 PFE@111 5/8: " PFE made it clear that they are a powerhouse marketer and going to get stronger". 7/10/98 PFE@115 5/8: "Viagra sales will approach $1 billion this year and possibly $8 billion at peak (2005)....PFE just blew us out of the water. And we haven't seen the impact yet of the international market where Viagra won't be sold for several months." Broker: Schroder & Co. Analyst: Jami Rubin PFE Rating: Outperform Target Price: $130 Comments: 7/10/98 PFE@115 5/8: "PFE's high P/E multiple, makes it vulnerable to any disappointments, but weakness creates a great long-term buy opportunity." Broker: Morgan Stanley Dean Witter Analyst: Paul A. Brooke Date: 7/10/98 PFE Rating: Outperform Target Price: $120 Buy/Attractive Broker: Salomon Smith Barney Analyst: Christina Heuer PFE Rating: Buy Target Price: $155 Comments: 7/03/98 PFE @107 1/2: "Zeldox is not dead yet. But the drug is in limbo until PFE discloses the results of its pow-wow with FDA. Best case: delayed 6-18 months while PFE generates additional data or re-analyzes current data. Worst case: Zeldox is never approved by FDA." Broker: Gerard Klauer Mattison Analyst: Cynthia A. Beach PFE Rating: Buy Target Price: $140 Comments: 7/10/98 PFE@115 5/8: "PFE's robust pipeline of new products is expected to provide earnings growth well into the next decade, but much of PFE's current price is based on anticipated significant sales of Viagra." Broker: Warburg Dillon Read Inc Analyst: Jerome R. Brimeyer Date: 7/10/98 PFE Rating: Buy Target Price: $135 Broker: NationsBanc Montgomery Securities Analyst: Leonard S. Yaffe MD PFE Rating: Buy Target Price: $132 Comments: 7/14/98 PFE@118 11/16: "With its aggressive near-term investment, impressive line of differentiated products, minimal patent exposure and strong pipeline, PFE has among the best fundamentals in the pharmaceutical industry and tremendous earnings potential." 7/10/98 PFE@ 115 5/8: "The drug of the year is Viagra, but PFE has in hand what should be next year's drug of the year (Celebra). (Earnings) were driven by Viagra, which beat our estimates by a couple of million $." Broker: J.P. Morgan Securities Analyst: Carl J. Seiden Date: 7/10/98 PFE Rating: Buy Target Price: $131 Comments: 7/10/98 PFE@ 115 5/8: "PFE is best in industry". Broker: Merrill Lynch Analyst: Steven C. Tighe PFE Rating: Buy: Near-term and long-term Target Price: Unknown Comments: 7/10/98 PFE@ 115 5/8: "Viagra sales were better than expected....It is likely Celebra will receive expedited review with a launch as early as 1/99.....The company's expectation is Viagra will be introduced in 50 countries by the end of the year." Broker: A.G. Edwards Analyst: Kenneth R. Nover PFE Rating: Buy Target Price: Unknown Comments: 7/13/98: PFE@118: "We currently recommend investors to overweight drug stocks...As the strongest large-market capitalization drug stock, we recommend PFE." Broker: PaineWebber Inc. Analyst: Jeffrey Chaffkin Date: 7/10/98 PFE Rating: Attractive Target Price: $130 Hold/Neutral Broker: Furman Selz Analyst: James Flynn PFE Rating: Hold Target Price: Unknown Comments: 7/10/98 PFE@ 115 5/8: "We do not recommend over-weighted PFE positions at this time given the prevalence of highly enthusiastic earnings expectations, management's more cautionary guidance, the present growth curve of Viagra and the company's already generous valuation...Third quarter Viagra sales will come in less than $100 million." 7/07/98 PFE@109 7/16: "Consider our present peak Viagra estimate of $2 billion (2002) to be potentially high". Broker: Brown Brothers Harriman Analyst: Michael Krensavage Date: 7/10/98 PFE Rating: Neutral Target Price: Unknown Comments: 7/10/98 PFE@ 115 5/8: "The question is how much reuse will (Viagra) get.The bottom line is that it's a highly effective drug." Broker: HKS & Co Analyst: Hemandt Shah PFE Rating: Neutral Target Price: Unknown Comments: 7/10/98 PFE@ 115 5/8: "PFE is doing well across the board..(Viagra ) had just a phenomenal performance. Certainly, Viagra will continue to grow. The real question is by how much." Broker: Lehman Brothers Analyst: Butler PFE Rating: Neutral Target Price: Unknown Comments: 7/17/98 PFE@ 117 13/16: "With several blockbusters and relatively few patent expirations, PFE has become a premier pharmaceutical company, however at 46 times 1999E EPS, we feel PFE is fully valued." Ratings Unknown Broker: Global Securities Analyst: Marcel Brichon Date: 7/07/98 PFE Rating: Unknown Target Price: Unknown Comments: 7/07/98 PFE@109 7/16: "PFE's a great hold for all its other products..Once the hesitancy (over Viagra) comes out of the marketplace, I expect strong growth." Broker: Bear Stearns Analyst: Shevick PFE Rating: Unknown Target Price: Unknown Comments: 7/21/98 PFE@117 15/16: "Viagra is expected to receive EU marketing authorization in 9/98." 7/10/98 PFE@ 115 5/8: "Viagra Rxs appear to be stabilizing and two year acceleration of Viagra's approval/launch in Japan, we consider to be a significant positive." Broker: Alex Brown Analyst: Ryan PFE Rating: Unknown Target Price: Unknown Comments: 7/10/98 PFE@ 115 5/8: "To date, we have admittedly been wrong and missed the stock, but do believe that these next couple weeks/months of Viagra Rxs will be the key focus of investors to see the sustainability of the product. If Viagra continues to perform and exceed expectations, we expect estimates to continue to rise, however, if there is a continued slowdown, investors beware."